{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:46:32Z","timestamp":1775238392045,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clinre.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:26:25Z","timestamp":1521159985000},"page":"313-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-0755","authenticated-orcid":false,"given":"Victor","family":"Virlogeux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Berthillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bordes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Larrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Crouy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Scholt\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Chemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Tr\u00e9po","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2018.02.002_bib0065","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","article-title":"Epidemiology of hepatitis C virus infection","volume":"13","author":"Alter","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2018.02.002_bib0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jhep.2008.07.005","article-title":"Acute hepatitis C: current status and remaining challenges","volume":"49","author":"Santantonio","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2018.02.002_bib0075","doi-asserted-by":"crossref","first-page":"44385","DOI":"10.1074\/jbc.M304047200","article-title":"Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope","volume":"278","author":"Petit","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinre.2018.02.002_bib0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2005.03.023","article-title":"Enveloped particles in the serum of chronic hepatitis C patients","volume":"336","author":"Petit","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.clinre.2018.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23862","article-title":"Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus","volume":"52","author":"Ndongo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2018.02.002_bib0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3851\/IMP2671","article-title":"Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes","volume":"18","author":"Arnaud","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.clinre.2018.02.002_bib0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clinre.2015.03.002","article-title":"Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases","volume":"39","author":"Petit","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2018.02.002_bib0100","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinre.2018.02.002_bib0105","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S0168-8278(16)01134-X","article-title":"Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimen: maintenance of SVR, persitence of resistance mutations and clinical outcomes","volume":"64","author":"Lawitz","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2018.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","article-title":"Prevention and management of treatment failure to new oral hepatitis C drugs","volume":"17","author":"Ben\u00edtez-Guti\u00e9rrez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinre.2018.02.002_bib0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinre.2013.08.003","article-title":"Predictors of the therapeutic response in hepatitis C. A 2013 update","volume":"38","author":"Arnaud","year":"2014","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2018.02.002_bib0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2016.04.006","article-title":"Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens","volume":"65","author":"Maasoumy","year":"2016","journal-title":"J Hepatol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118300342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118300342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:27:13Z","timestamp":1761895633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740118300342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2210740118300342"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2018.02.002","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}